Skip to main content

CORRECTION article

Front. Pharmacol., 31 January 2023
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1140018

Corrigendum: Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carcinoma via network pharmacology and experimental validation

This article is a correction to:

  1. Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carcinoma via network pharmacology and experimental validation

    1. Read original article
Minglu LiuMinglu Liu1Tong Hu,Tong Hu2,3Wenfeng GouWenfeng Gou2Huajie ChangHuajie Chang2Yanli LiYanli Li2Yiliang LiYiliang Li2Daiying ZuoDaiying Zuo3Wenbin Hou Wenbin Hou2*Shunchang Jiao Shunchang Jiao1*
  • 1Department of Medical Oncology, The First Medical Centre, Chinese People’s Liberation Army General Hospital, Beijing, China
  • 2Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China
  • 3Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China

A Corrigendum on
Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carcinoma via network pharmacology and experimental validation

by Liu M, Hu T, Gou W, Chang H, Li Y, Li Y, Zuo D, Hou W and Jiao S (2022) Front. Pharmacol. 13:993022. doi: 10.3389/fphar.2022.993022

In the published article, there was an error in the Author list. The corrected author list appears below:

“Minglu Liu1, Tong Hu2,3, Wenfeng Gou2, Huajie Chang2, Yanli Li2, Yiliang Li2, Daiying Zuo3, Wenbin Hou2,*, Shunchang Jiao1,*”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: icaritin, nasopharyngeal carcinoma, ROS, senescence, network pharmacology

Citation: Liu M, Hu T, Gou W, Chang H, Li Y, Li Y, Zuo D, Hou W and Jiao S (2023) Corrigendum: Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carcinoma via network pharmacology and experimental validation. Front. Pharmacol. 14:1140018. doi: 10.3389/fphar.2023.1140018

Received: 08 January 2023; Accepted: 25 January 2023;
Published: 31 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Liu, Hu, Gou, Chang, Li, Li, Zuo, Hou and Jiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wenbin Hou, houwenbin@irm-cams.ac.cn; Shunchang Jiao, jiaoshunchang@csco.org.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.